Biotalys Raises 12.05 Million Euros Through Private Placement with a 40% Discount
Biotalys announced on Wednesday the successful completion of a private placement with its existing shareholders, raising 12.05 million euros. The transaction involved the issuance of 7,875,811 new shares at 1.53 euros each, representing a capital increase of approximately 20.96%.
The private placement engaged institutional and strategic investors already part of the capital: Ackermans & van Haaren NV, Agri Investment Fund BV, ASR Vermogensbeheer NV, Federale Participatie- en Investeringsmaatschappij NV, Gimv NV, PMV NV, Sofinnova Industrial Biotech I, and the Flanders Institute for Biotechnology (VIB). The issue price of 1.53 euros per share represents a 40% discount compared to the weighted average of the stock prices over the last thirty days of trading (from April 1 to April 30, 2026).
New shareholders have committed to a three-month lock-up period for their shares (both new and old) starting from the closure of the transaction. The delivery of the securities is scheduled around May 20, 2026, from which date the new shares will be admitted for trading on Euronext Brussels.
Allocation of Funds and Strategic Milestones
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Biotalys plans to use the proceeds from this capital raise to support the development of its precision biocontrol solutions based on proteins, aimed at the crop protection markets before and after harvest. The company is targeting several milestones in the near future: regulatory approval of Evoca in the European Union, product registration in California, conducting field trials with a leading candidate from the BioFun-6 range, optimizing its production process in partnership with 21st.BIO, and continuing existing collaborations with Syngenta, the Gates Foundation, and its partner AgroFresh in the post-harvest market.
Related
SectorProduits Chimiques›Engrais
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2025
Guidance from the release
En 2025, nous avons atteint un point d'inflexion majeur avec l'approbation de notre premier biocontrole.
Nous renforçons notre concentration sur les programmes de biofongicides les plus avancés.
Risks mentioned
Biotalys n'a pas suffisamment de fonds de roulement pour couvrir ses besoins pendant au moins 12 mois.
La société a seulement une visibilité de trésorerie jusqu'à fin mai 2026.
Opportunities identified
Partenariat stratégique avec AgroFresh pour le marché post-récolte.
Développement de programmes avancés de biofongicides.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
